TY - JOUR
T1 - Workshop on umbilical cord blood stem cells and transplantation - Keystone Symposia
AU - Gluckman, E.
AU - Wagner, J.
PY - 1995
Y1 - 1995
N2 - In an attempt to reduce the morbidity and mortality associated with allogeneic bone marrow transplantation, clinical investigators in Asia, Australia, Europe and North America have evaluated umbilical cord and placental blood as an alternate source of hematopoietic stem and progenitor cells for transplantation. To date, 34 patients with a variety of malignant and non malignant diseases have been transplanted with umbilical cord blood after myeloablative therapy. The clinical outcome after transplantation, hematopoietic content of umbilical cord blood, maternal cell contamination, functional aspects of the neonatal immune system and issues related to the large scale banking of unrelated umbilical cord blood are summarized in this review.
AB - In an attempt to reduce the morbidity and mortality associated with allogeneic bone marrow transplantation, clinical investigators in Asia, Australia, Europe and North America have evaluated umbilical cord and placental blood as an alternate source of hematopoietic stem and progenitor cells for transplantation. To date, 34 patients with a variety of malignant and non malignant diseases have been transplanted with umbilical cord blood after myeloablative therapy. The clinical outcome after transplantation, hematopoietic content of umbilical cord blood, maternal cell contamination, functional aspects of the neonatal immune system and issues related to the large scale banking of unrelated umbilical cord blood are summarized in this review.
UR - http://www.scopus.com/inward/record.url?scp=0029069991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029069991&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0029069991
SN - 0268-3369
VL - 15
SP - S146-S150
JO - Bone marrow transplantation
JF - Bone marrow transplantation
IS - SUPPL. 1
ER -